Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Adrenergic Agonists: Direct-Acting Agents01:30

Adrenergic Agonists: Direct-Acting Agents

Drugs that mimic the action of endogenous catecholamines like noradrenaline and adrenaline are called adrenergic agonists or sympathomimetics. Based on their mechanism of action, sympathomimetics can be classified as direct-, indirect-, or mixed-acting sympathomimetics. Direct-acting adrenergic agonists activate adrenoceptors without affecting presynaptic neurons, making them independent of neuronal catecholamine-depleting agents like reserpine and guanethidine.
These agents can be classified...
Adrenergic Agonists: Indirect-Acting Agents01:25

Adrenergic Agonists: Indirect-Acting Agents

Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
Adrenergic Agonists: Mixed-Action Agents01:28

Adrenergic Agonists: Mixed-Action Agents

Mixed-action adrenergic agonists, like ephedrine and pseudoephedrine, directly and indirectly affect adrenergic receptors. These agents stimulate adrenoceptors and indirectly release stored neurotransmitters, amplifying the adrenergic response.
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
Adrenergic Agonists: Chemistry and Structure-Activity Relationship01:16

Adrenergic Agonists: Chemistry and Structure-Activity Relationship

Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of the aromatic...
Adrenergic Agonists: Therapeutic Uses01:30

Adrenergic Agonists: Therapeutic Uses

Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and anaphylaxis:...
Antiasthma Drugs: β2-Adrenoceptor Agonists01:25

Antiasthma Drugs: β2-Adrenoceptor Agonists

Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Large-scale molecular endotype discovery in synovial fluid reveals osteoarthritis as a single biological continuum.

Nature communications·2026
Same author

The alarmins high mobility group box protein 1 and S100A8/A9 display different inflammatory profiles after acute knee injury.

Osteoarthritis and cartilage·2022
Same author

Investigating the Nature of Late-Time High-Energy GRB Emission Through Joint <i>Fermi /Swift</i> Observations.

The Astrophysical journal·2022
Same author

<i>Fermi</i> LARGE AREA TELESCOPE OBSERVATIONS OF BLAZAR 3C 279 OCCULTATIONS BY THE SUN.

The Astrophysical journal·2021
Same author

Measurement of the high-energy gamma-ray emission from the Moon with the Fermi Large Area Telescope.

Physical review. D. (2016)·2020
Same author

Molecular and imaging biomarkers of local inflammation at 2 years after anterior cruciate ligament injury do not associate with patient reported outcomes at 5 years.

Osteoarthritis and cartilage·2020

Related Experiment Video

Updated: May 8, 2026

Construction and Implantation of a Microinfusion System for Sustained Delivery of Neuroactive Agents.
12:17

Construction and Implantation of a Microinfusion System for Sustained Delivery of Neuroactive Agents.

Published on: March 18, 2008

Long-term studies on long-acting sympathomimetics.

S Larsson1

  • 1Department of Pulmonary Medicine, Gothenburg University, Göteborg, Sweden.

Lung
|January 1, 1990
PubMed
Summary
This summary is machine-generated.

Long-acting beta 2-agonists like formoterol and salmeterol offer superior asthma symptom relief and patient preference. These medications provide better bronchodilation without developing tolerance, though they may mask worsening asthma conditions.

More Related Videos

A Reversible, Non-invasive Method for Airway Resistance Measurements and Bronchoalveolar Lavage Fluid Sampling in Mice
09:58

A Reversible, Non-invasive Method for Airway Resistance Measurements and Bronchoalveolar Lavage Fluid Sampling in Mice

Published on: April 13, 2010

A General Method for Evaluating Deep Brain Stimulation Effects on Intravenous Methamphetamine Self-Administration
09:16

A General Method for Evaluating Deep Brain Stimulation Effects on Intravenous Methamphetamine Self-Administration

Published on: January 22, 2016

Related Experiment Videos

Last Updated: May 8, 2026

Construction and Implantation of a Microinfusion System for Sustained Delivery of Neuroactive Agents.
12:17

Construction and Implantation of a Microinfusion System for Sustained Delivery of Neuroactive Agents.

Published on: March 18, 2008

A Reversible, Non-invasive Method for Airway Resistance Measurements and Bronchoalveolar Lavage Fluid Sampling in Mice
09:58

A Reversible, Non-invasive Method for Airway Resistance Measurements and Bronchoalveolar Lavage Fluid Sampling in Mice

Published on: April 13, 2010

A General Method for Evaluating Deep Brain Stimulation Effects on Intravenous Methamphetamine Self-Administration
09:16

A General Method for Evaluating Deep Brain Stimulation Effects on Intravenous Methamphetamine Self-Administration

Published on: January 22, 2016

Area of Science:

  • Pulmonology
  • Pharmacology

Background:

  • Inhaled long-acting beta 2-agonists are commonly used for asthma management.
  • Patient preference and efficacy are key considerations in long-term asthma treatment.

Purpose of the Study:

  • To evaluate the long-term efficacy and patient acceptance of formoterol and salmeterol.
  • To assess the development of tolerance and potential masking of asthma deterioration with these agents.

Main Methods:

  • Review of long-term treatment studies comparing formoterol and salmeterol to other beta 2-agonists.
  • Analysis of patient-reported outcomes, symptom reduction, and need for additional medication.
  • Examination of case histories for evidence of tolerance or masked disease progression.

Main Results:

  • Formoterol and salmeterol demonstrated superior bronchodilation compared to other available beta 2-agonists.
  • Patients reported decreased asthma symptoms and a reduced need for supplemental medication.
  • No development of tolerance was observed in long-term studies.
  • A case history suggested these agents might mask underlying asthma deterioration.

Conclusions:

  • Long-term use of formoterol and salmeterol offers significant benefits in asthma control and patient satisfaction.
  • While effective and well-tolerated, clinicians should remain vigilant for potential masking of worsening asthma.
  • These findings support the continued use of formoterol and salmeterol in appropriate asthma management strategies.